Advancing first-in-class therapies to restore energy homeostasis
Palo Alto, CA
Joined October 2022
- Tweets7
- Following3
- Followers60
- Likes10
Today we announced Ph 1 data for TLC-2716, a liver-targeted LXR inverse agonist in development for severe hypertriglyceridemia/#NASH, to be presented at #AHA23. The data demonstrate dose-dependent improvements in plasma TGs, LDL-C, LDL particles and apoB. bwnews.pr/3sweuii
Today we announced Phase 1 data for our liver-targeted, mitochondrial protonophore, TLC-6740, at #ObesityWeek. Preliminary data suggest TLC-6740 is well tolerated and will reach therapeutic exposures at low doses. Read more here: tinyurl.com/OrsoBio #obesity #diabetes #NASH
Today we announced dosing of the first patient in our Phase 2a trial of the ACC2-selective inhibitor TLC-3595 for the treatment of #diabetes. Read more about this important milestone: bwnews.pr/3TvGmw3
OrsoBio retweeted
A new biotech just dropped with a basket of assets, including two clinical-stage ones, from Gilead, Shionogi, Phenex Pharmaceuticals, Astellas’ Mitobridge and Yale.
endpts.com/samsara-backs-ex-…
OrsoBio retweeted
OrsoBio launched Tuesday with Gilead alums Mani Subramanian, M.D., in the CEO seat and Rob Myers, M.D., serving as chief medical officer.
fiercebiotech.com/biotech/5-…
We’re excited to announce the launch of OrsoBio as we embark on our mission to redefine the treatment of metabolic diseases. Special thanks to our scientific advisors (Dr. G. Shulman, @Auwerx_Lab, @TakebeLab) and @SamsaraBioCap for their support! bwnews.pr/3TacLqx